Skip to main content
Log in

Standardtherapie der Tuberkulose

Standard therapy of tuberculosis

  • Schwerpunkt: Tuberkulose
  • Published:
Der Internist Aims and scope Submit manuscript

An Erratum to this article was published on 25 May 2016

Zusammenfassung

Basierend auf Studien der 1960er- bis 1980er-Jahre wurde die heutige Vierfachtherapie der Tuberkulose als Standard- oder Kurzzeittherapie weltweit etabliert. Die regionale Epidemiologie sowie die Besonderheiten der nationalen Gesundheitssysteme machen Anpassungen der globalen Empfehlungen notwendig. In den letzten Jahren wurden diese Anpassungen durch die Therapieempfehlungen des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose (DZK e. V.) vorgenommen. Die aktuell zunehmende Migration aus Ländern mit höherer Inzidenz lässt einen Anstieg der Tuberkulosefälle erwarten, sodass der oftmals sporadische Kontakt mit Tuberkulosepatienten auch in der Praxis des Niedergelassenen häufiger werden wird. Eine umfassende S2k-Leitlinie zur Tuberkulosetherapie für Kinder und Erwachsene wird derzeit nach den Vorgaben der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) erstellt. Vor Fertigstellung der umfassenden Leitlinie werden hier einige praktische Hinweise zur Diagnostik und Therapie der unkomplizierten Tuberkulose zusammengefasst, damit den aktuellen Herausforderungen begegnet werden kann.

Abstract

Based on the results of studies from the 1960s–1980s the current four drug combination therapy was established as standard or short course tuberculosis therapy worldwide. The regional epidemiology and the often unique conditions within a national health system create the need for specific adjustments. Over the last years these were realized by the German central committee against tuberculosis (DZK) in the recommendations for tuberculosis therapy. Because of the recent development of migration into Germany from countries with higher tuberculosis incidences an increase in tuberculosis cases is to be expected. The expected increase in tuberculosis cases will lead to more contact with tuberculosis patients even in the outpatient setting. New S2k guidelines guided by the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) for the treatment of tuberculosis for children and adults are under development. Before the release of the comprehensive guidelines, practical evidence for the diagnosis and treatment of uncomplicated tuberculosis is summarized in this document to meet the challenges of the recent developments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Robert Koch-Institut (2015) Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2014

  2. Yew WW, Lange C, Leung CC (2011) Treatment of tuberculosis: update 2010. Eur Respir J 37(2):441–462

    Article  CAS  PubMed  Google Scholar 

  3. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G et al (2011) Efficacy and safety of a 4‑drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 305(14):1415–1423

    Article  CAS  PubMed  Google Scholar 

  4. Alsultan A, Peloquin CA (2014) Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74(8):839–854

    Article  CAS  PubMed  Google Scholar 

  5. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM et al (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174(8):935–952

    Article  CAS  PubMed  Google Scholar 

  6. Schaberg T, Bauer T, Castell S, Dalhoff K, Detjen A, Diel R et al (2012) Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP). Pneumol Stuttg Ger 66(3):133–171

    Article  CAS  Google Scholar 

  7. http://www.pneumologie.de/dzk/patientenservice.html. Zugegriffen: 10. Dezember 2015

  8. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K et al (2012) Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109(38):15449–15454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP et al (2011) High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377(9761):242–250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F (2013) Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study (Supplementary Cholecalciferol in recovery from tuberculosis). A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. Bmc Infect Dis 13:22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Vilchèze C, Hartman T, Weinrick B, Jacobs WR Jr. (2013) Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C‑induced Fenton reaction. Nat Commun 4:1881

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR (2013) Acceleration of tuberculosis treatment by adjunctive therapy with Verapamil as an efflux inhibitor. Am J Respir Crit Care Med 188(5):600–607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR et al (2014) Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371(17):1577–1587

    Article  PubMed  PubMed Central  Google Scholar 

  14. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA et al (2015) Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385(9979):1738–1747

    Article  CAS  PubMed  Google Scholar 

  15. http://www.vfa.de/de/nachrichten/pm20140320. Zugegriffen: 24. Oktober 2015

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Otto-Knapp.

Ethics declarations

Interessenkonflikt

R. Otto-Knapp, K. Schenkel und T. Bauer geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

B. Salzberger, Regensburg

T. Welte, Hannover

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Otto-Knapp, R., Schenkel, K. & Bauer, T. Standardtherapie der Tuberkulose. Internist 57, 117–125 (2016). https://doi.org/10.1007/s00108-016-0031-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-016-0031-0

Schlüsselwörter

Keywords

Navigation